# Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

> **NCT05243199** · PHASE4 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 330 (actual)

## Conditions studied

- CKD5 Stage Dialysis
- Heart Failure

## Interventions

- **DRUG:** Sacubitril/Valsartan
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT05243199
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-08
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243199, "Sacubitril/Valsartan for CKD5 Stage Dialysis Patients". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05243199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*